Injectable Excipients As Novel Influenza Vaccine Adjuvants

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2019 Feb 9

PMID 30733711

Citations 7

Authors

Huapeng Feng

Makoto Yamashita

Tiago Jose da Silva Lopes

Tokiko Watanabe

Yoshihiro Kawaoka

Affiliations

Soon will be listed here.

Abstract

Influenza outbreaks can be either seasonal or pandemic. Vaccination is an effective strategy to control influenza; however, the efficacy of the currently available inactivated influenza virus vaccines is suboptimal, especially in the elderly. Vaccine efficacy can be improved by the addition of adjuvants, but few adjuvants have been approved for human vaccines. To explore novel, safe, and effective adjuvants for influenza vaccines, here we used a mouse model to screen 46 injectable drug additives approved in Japan. Of these 46 candidates, we identified 20 compounds that enhanced the efficacy of the split influenza HA vaccine against lethal virus challenge. These 20 compounds included 15 novel adjuvant candidates and 5 compounds with previously reported adjuvant effects for other antigens but not for influenza vaccine. Given that these additives are already approved for human use, the hurdle for their clinical use as novel and effective adjuvants for influenza or other vaccines is lower than for other adjuvant candidates whose safety profiles are unknown.

Citing Articles

H9 Consensus Hemagglutinin Subunit Vaccine with Adjuvants Induces Robust Mucosal and Systemic Immune Responses in Mice by Intranasal Administration.

Lin L, Zhu S, Yang B, Zhang X, Wu H, Wu S Microorganisms. 2024; 12(11).

PMID: 39597683 PMC: 11596065. DOI: 10.3390/microorganisms12112294.

Basic Properties and Development Status of Aluminum Adjuvants Used for Vaccines.

Lan J, Feng D, He X, Zhang Q, Zhang R Vaccines (Basel). 2024; 12(10).

PMID: 39460352 PMC: 11511158. DOI: 10.3390/vaccines12101187.

A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine.

Feng H, Sun R, Song G, Zhu S, Nie Z, Lin L Viruses. 2022; 14(6).

PMID: 35746644 PMC: 9230830. DOI: 10.3390/v14061174.

Prolonged Codelivery of Hemagglutinin and a TLR7/8 Agonist in a Supramolecular Polymer-Nanoparticle Hydrogel Enhances Potency and Breadth of Influenza Vaccination.

Roth G, Saouaf O, Smith A, Gale E, Hernandez M, Idoyaga J ACS Biomater Sci Eng. 2021; 7(5):1889-1899.

PMID: 33404236 PMC: 8153386. DOI: 10.1021/acsbiomaterials.0c01496.

Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine.

Feng H, Nakatsu S, da Silva Lopes T, Imai M, Yamayoshi S, Yamashita M Vaccines (Basel). 2020; 8(2).

PMID: 32397625 PMC: 7349346. DOI: 10.3390/vaccines8020215.

References

Fukanoki S, Matsumoto K, Mori H, Takeda R . Relationship between antigen release and antibody response of infectious coryza water-in-oil-in-water emulsion vaccines. Avian Dis. 2001; 44(4):869-73. View

Garcon N, Chomez P, Van Mechelen M . GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007; 6(5):723-39. DOI: 10.1586/14760584.6.5.723. View

Fukanoki S, Iwakura T, Iwaki S, Matsumoto K, Takeda R, Ikeda K . Safety and efficacy of water-in-oil-in-water emulsion vaccines containing Newcastle disease virus haemagglutinin-neuraminidase glycoprotein. Avian Pathol. 2009; 30(5):509-16. DOI: 10.1080/03079450120078707. View

Didierlaurent A, Morel S, Lockman L, Giannini S, Bisteau M, Carlsen H . AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol. 2009; 183(10):6186-97. DOI: 10.4049/jimmunol.0901474. View

Even-Or O, Samira S, Rochlin E, Balasingam S, Mann A, Lambkin-Williams R . Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine. Vaccine. 2010; 28(39):6527-41. DOI: 10.1016/j.vaccine.2010.04.011. View

Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V . Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011; 29(13):2461-73. DOI: 10.1016/j.vaccine.2011.01.011. View

Sakabe S, Ozawa M, Takano R, Iwastuki-Horimoto K, Kawaoka Y . Mutations in PA, NP, and HA of a pandemic (H1N1) 2009 influenza virus contribute to its adaptation to mice. Virus Res. 2011; 158(1-2):124-9. PMC: 3103651. DOI: 10.1016/j.virusres.2011.03.022. View

Manzoli L, De Vito C, Salanti G, DAddario M, Villari P, Ioannidis J . Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PLoS One. 2011; 6(9):e24384. PMC: 3167852. DOI: 10.1371/journal.pone.0024384. View

Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J . AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One. 2012; 7(3):e33536. PMC: 3314666. DOI: 10.1371/journal.pone.0033536. View

10.

Das S, Hatta M, Wilker P, Myc A, Hamouda T, Neumann G . Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine. 2012; 30(48):6871-7. PMC: 3488283. DOI: 10.1016/j.vaccine.2012.09.007. View

11.

Tetsutani K, Ishii K . Adjuvants in influenza vaccines. Vaccine. 2012; 30(52):7658-61. DOI: 10.1016/j.vaccine.2012.10.007. View

12.

Shakya A, Nandakumar K . Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases. J R Soc Interface. 2012; 10(79):20120536. PMC: 3565688. DOI: 10.1098/rsif.2012.0536. View

13.

Szakacs A, Darin N, Hallbook T . Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology. 2013; 80(14):1315-21. DOI: 10.1212/WNL.0b013e31828ab26f. View

14.

Fox C, Haensler J . An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines. 2013; 12(7):747-58. DOI: 10.1586/14760584.2013.811188. View

15.

Joo I, Emod J . Adjuvant effect of DEAE-dextran on cholera vaccines. Vaccine. 1988; 6(3):233-7. DOI: 10.1016/0264-410x(88)90217-4. View

16.

Uraki R, Das S, Hatta M, Kiso M, Iwatsuki-Horimoto K, Ozawa M . Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine. Vaccine. 2014; 32(41):5295-300. PMC: 6312188. DOI: 10.1016/j.vaccine.2014.07.079. View

17.

Onishi M, Ozasa K, Kobiyama K, Ohata K, Kitano M, Taniguchi K . Hydroxypropyl-β-cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antigen. J Immunol. 2015; 194(6):2673-82. PMC: 4470223. DOI: 10.4049/jimmunol.1402027. View

18.

Galliher-Beckley A, Pappan L, Madera R, Burakova Y, Waters A, Nickles M . Characterization of a novel oil-in-water emulsion adjuvant for swine influenza virus and Mycoplasma hyopneumoniae vaccines. Vaccine. 2015; 33(25):2903-8. DOI: 10.1016/j.vaccine.2015.04.065. View

19.

Chambers B, Parkhouse K, Ross T, Alby K, Hensley S . Identification of Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 2014-2015 Influenza Season. Cell Rep. 2015; 12(1):1-6. PMC: 4487778. DOI: 10.1016/j.celrep.2015.06.005. View

20.

Petrovsky N . Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs. Drug Saf. 2015; 38(11):1059-74. PMC: 4615573. DOI: 10.1007/s40264-015-0350-4. View